Food as a vehicle for antimicrobial resistance: submit your articles that fit our annual theme
Check the detailsCoronavirus disease 2019 (COVID-19) Read our collection
Eurosurveillance: 1996 to 2021
25 years of public health impact Read our anniversary collectionLooking at the benefits and risks, efficacy and vaccine effectiveness
Read our COVID-19 vaccines collectionInterested in evidence related to children and COVID-19? Find it in our collection
Eurosurveillance
Since 1995, Eurosurveillance has provided the European public health community with an open-access platform to exchange relevant findings on communicable disease surveillance, prevention and control. A weekly, electronic, peer-reviewed publication, Eurosurveillance aims to provide timely facts and guidance for public health professionals and decision-makers in the field of infectious disease to facilitate the implementation of effective prevention and control measures. Impact factor: 6.3. More...
Latest Issue: Volume 27, Issue 20, 19 May 2022 Latest Issue RSS feed
- Editorial
- Rapid communication
-
-
-
Risk and protective factors for SARS-CoV-2 reinfections, surveillance data, Italy, August 2021 to March 2022
We explored the risk factors associated with SARS-CoV-2 reinfections in Italy between August 2021 and March 2022. Regardless of the prevalent virus variant, being unvaccinated was the most relevant risk factor for reinfection. The risk of reinfection increased almost 18-fold following emergence of the Omicron variant compared with Delta. A severe first SARS-CoV-2 infection and age over 60 years were significant risk factors for severe reinfection.
-
-
-
mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022
For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95–96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79–84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.
-
- Top
-
- Research
-
-
-
Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study
Tal Brosh-Nissimov , Yasmin Maor , Meital Elbaz , Shelly Lipman-Arens , Yonit Wiener-Well , Khetam Hussein , Efrat Orenbuch-Harroch , Regev Cohen , Oren Zimhony , Bibiana Chazan , Lior Nesher , Galia Rahav , Hiba Zayyad , Mirit Hershman-Sarafov , Miriam Weinberger , Ronza Najjar-Debbiny and Michal ChowersBackgroundChanging patterns of vaccine breakthrough can clarify vaccine effectiveness.
AimTo compare breakthrough infections during a SARS-CoV-2 Delta wave vs unvaccinated inpatients, and an earlier Alpha wave.
MethodsIn an observational multicentre cohort study in Israel, hospitalised COVID-19 patients were divided into three cohorts: breakthrough infections in Comirnaty-vaccinated patients (VD; Jun–Aug 2021) and unvaccinated cases during the Delta wave (ND) and breakthrough infections during an earlier Alpha wave (VA; Jan–Apr 2021). Primary outcome was death or ventilation.
ResultsWe included 343 VD, 162 ND and 172 VA patients. VD were more likely older (OR: 1.06; 95% CI: 1.05–1.08), men (OR: 1.6; 95% CI: 1.0–2.5) and immunosuppressed (OR: 2.5; 95% CI: 1.1–5.5) vs ND. Median time between second vaccine dose and admission was 179 days (IQR: 166–187) in VD vs 41 days (IQR: 28–57.5) in VA. VD patients were less likely to be men (OR: 0.6; 95% CI: 0.4–0.9), immunosuppressed (OR: 0.3; 95% CI: 0.2–0.5) or have congestive heart failure (OR: 0.6; 95% CI: 0.3–0.9) vs VA. The outcome was similar between all cohorts and affected by age and immunosuppression and not by vaccination, variant or time from vaccination.
ConclusionsVaccination was protective during the Delta variant wave, as suggested by older age and greater immunosuppression in vaccinated breakthrough vs unvaccinated inpatients. Nevertheless, compared with an earlier post-vaccination period, breakthrough infections 6 months post-vaccination occurred in healthier patients. Thus, waning immunity increased vulnerability during the Delta wave, which suggests boosters as a countermeasure.
-
-
-
Assessment of mortality and hospital admissions associated with confirmed infection with SARS-CoV-2 Alpha variant: a matched cohort and time-to-event analysis, England, October to December 2020
Gavin Dabrera , Hester Allen , Asad Zaidi , Joe Flannagan , Katherine Twohig , Simon Thelwall , Elizabeth Marchant , Nurin Abdul Aziz , Theresa Lamagni , Richard Myers , André Charlett , Fernando Capelastegui , Dimple Chudasama , Tom Clare , Flavien Coukan , Mary Sinnathamby , Neil Ferguson , Susan Hopkins , Meera Chand , Russell Hope , Meaghan Kall and on behalf of the COG-UK ConsortiumBackgroundThe emergence of the SARS-CoV-2 Alpha variant in England coincided with a rapid increase in the number of PCR-confirmed COVID-19 cases in areas where the variant was concentrated.
AimOur aim was to assess whether infection with Alpha was associated with more severe clinical outcomes than the wild type.
MethodsLaboratory-confirmed infections with genomically sequenced SARS-CoV-2 Alpha and wild type between October and December 2020 were linked to routine healthcare and surveillance datasets. We conducted two statistical analyses to compare the risk of hospital admission and death within 28 days of testing between Alpha and wild-type infections: a matched cohort study and an adjusted Cox proportional hazards model. We assessed differences in disease severity by comparing hospital admission and mortality, including length of hospitalisation and time to death.
ResultsOf 63,609 COVID-19 cases sequenced in England between October and December 2020, 6,038 had the Alpha variant. In the matched cohort analysis, we matched 2,821 cases with Alpha to 2,821 to cases with wild type. In the time-to-event analysis, we observed a 34% increased risk in hospitalisation associated with Alpha compared with wild type, but no significant difference in the risk of mortality.
ConclusionWe found evidence of increased risk of hospitalisation after adjusting for key confounders, suggesting increased infection severity associated with the Alpha variant. Rapid assessments of the relative morbidity in terms of clinical outcomes and mortality associated with emerging SARS-CoV-2 variants compared with dominant variants are required to assess overall impact of SARS-CoV-2 mutations.
-
- Top
-
- Author's correction
-
Recent articles
-
-
Trends in the epidemiology of catheter-related bloodstream infections; towards a paradigm shift, Spain, 2007 to 2019
Laia Badia-Cebada , Judit Peñafiel , Patrick Saliba , Marta Andrés , Jordi Càmara , Dolors Domenech , Emili Jiménez-Martínez , Anna Marrón , Encarna Moreno , Virginia Pomar , Montserrat Vaqué , Enric Limón , Úrsula Masats , Miquel Pujol , Oriol Gasch and on behalf of the VINCat programme (Infection Control Catalan Programme)
-
-
-
-